SCHEMBL8143194

SCHEMBL8143194

Nc1nnc(-c2ccccn2)s1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 12/20 0.74
NPC1 O15118 6/20 0.74
RAB9A P51151 5/20 0.74
MAPT P10636 2/20 0.74
ATM Q13315 1/20 0.74
ALDH1A1 P00352 9/20 0.50
GLA P06280 1/20 0.50
SMN1; SMN2 Q16637 5/20 0.49
HSD17B10 Q99714 6/20 0.49
TP53 P04637 5/20 0.49
HPGD P15428 3/20 0.49
TSHR P16473 2/20 0.49
LMNA P02545 2/20 0.48
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.48
CCR1 P32246 1/20 0.48
CCR5 P51681 1/20 0.48
CCR8 P51685 1/20 0.48
METAP1 P53582 1/20 0.48
BLM P54132 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1424929 0.86 KDM4E (1.00) KDM4ENPC1RAB9AMAPTATM
SCHEMBL3137543 0.84 KDM4E (0.53) KDM4ENPC1RAB9AMAPTATM
SCHEMBL1208215 0.79 KDM4E (0.70) KDM4ENPC1RAB9AMAPTATM
SCHEMBL29870798 0.78 KDM4E (0.77) KDM4ENPC1RAB9AMAPTATM
SCHEMBL15671504 0.78 KDM4E (0.77) KDM4ENPC1RAB9AMAPTATM
SCHEMBL22761302 0.78 KDM4E (0.69) KDM4ENPC1RAB9AMAPTATM
SCHEMBL11982530 0.77 KDM4E (0.74) KDM4ENPC1RAB9AMAPTATM
SCHEMBL971007 0.77 KDM4E (0.74) KDM4ENPC1RAB9AMAPTATM
SCHEMBL17135790 0.77 KDM4E (0.74) KDM4ENPC1RAB9AMAPTATM
SCHEMBL17835736 0.76 KDM4E (0.56) KDM4ENPC1RAB9AMAPTATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119751439-A ATF6 modulators and uses thereof 阿尔托斯实验室公司 2025-04-04 CN disclosed
CN-115087656-B ATF6 modulators and uses thereof 阿尔托斯实验室公司 2024-12-13 CN disclosed
US-20240270735-A1 CDK19-Selective Inhibitors, and Methods of Use Thereof CHAN ZUCKERBERG BIOHUB, INC. 2024-08-15 US disclosed
CN-112279845-B Aryl or heteroaryl substituted thiadiazoles compounds and antibacterial application thereof 中国医学科学院药物研究所 2023-07-28 CN disclosed
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ALTOS LABS, INC. 2023-01-26 US disclosed
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ALTOS LABS, INC. 2023-01-26 US disclosed
CN-115087656-A ATF6 modulators and uses thereof 普拉西斯生物技术有限责任公司 2022-09-20 CN disclosed
EP-4041728-A1 ATF6 MODULATORS AND USES THEREOF Praxis Biotech LLC (US) 2022-08-17 EP disclosed
WO-2021069721-A1 ATF6 MODULATORS AND USES THEREOF BLACK BELT TX LTD (GB) 2021-04-15 WO disclosed
WO-2021069721-A1 ATF6 MODULATORS AND USES THEREOF BLACK BELT TX LTD (GB) 2021-04-15 WO disclosed
CN-112279845-A Aryl or heteroaryl substituted thiadiazole compounds and antibacterial application thereof 中国医学科学院药物研究所 2021-01-29 CN disclosed
US-20170107212-A1 NOVEL COMPOUNDS Bayer Pharma AG (DE) 2017-04-20 US disclosed
EP-3119759-A1 NOVEL COMPOUNDS Bayer Pharma Aktiengesellschaft (DE) 2017-01-25 EP disclosed
WO-2015140195-A1 NOVEL COMPOUNDS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-09-24 WO disclosed
CN-104098609-A Imidazole and [2,1-b]-1,3,4-thiadiazole containing ferrocene, preparation method and application thereof UNIV SHAANXI SCIENCE & TECH 2014-10-15 CN disclosed
EP-1054876-A1 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS PHARMACIA & UPJOHN S.p.A. (IT) 2000-11-29 EP disclosed
WO-1999028309-A1 1,3,4-THIADIAZOLES DERIVATIVES AS KYN-OH INHIBITORS PHARMACIA & UPJOHN S.P.A. (IT) 1999-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240270735-A1 CDK19-Selective Inhibitors, and Methods of Use Thereof CDK19, CDK9, CDK1 KDM4E 904/4885NPC1 3644/4885RAB9A 651/4885
US-20170107212-A1 NOVEL COMPOUNDS WNT1, CTNNB1, WNT3A KDM4E 3482/4885NPC1 356/4885RAB9A 1164/4885
US-20230028584-A1 ATF6 MODULATORS AND USES THEREOF ATF4, XBP1, ATF1 KDM4E 4378/4885NPC1 179/4885RAB9A 2353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.